Tofacitinib Special Investigation Of Xeljanz Tablets 5mg. (Regulatory Post Marketing Commitment Plan)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Tofacitinib (Primary) ; Anti-TNF monoclonal antibodies; Disease-modifying antirheumatics; Etanercept; Tumour necrosis factor alpha inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 11 Jul 2017 Planned End Date changed from 1 Mar 2021 to 26 Jan 2021.
- 11 Jul 2017 Planned primary completion date changed from 1 Mar 2021 to 26 Jan 2021.
- 20 Feb 2017 Planned End Date changed from 1 Feb 2020 to 1 Mar 2021.